BiomeBank
A clinical stage biotechnology company developing microbial therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
AUD6.0m | Secondary | ||
| Total Funding | 000k | ||
Related Content
BiomeBank is a leading microbiome therapeutics company with a mission to restore human gut microbial ecology. BIOMICTRA,TM is the first approved donor derived microbiome therapy in the world (approved by TGA in 2022 for C.difficile infection).
BiomeBank’s CONSORTIOMETM drug development platform, leverages data from BIOMICTRA use in discovery trials in novel disease indications to create therapies disease specific cultured microbiome based therapies. The CONSORTIOME TM platform contains the ability to co-culture >100 of the most prevalent species covering >90% of known gene families in a healthy human gut microbiome into one drug substance.
Cultured therapy BB265 has been designed to treat ulcerative colitis and will enter a phase 1b/2a human study in 2025. Due to similar disease mechanisms, BB265 is expected to also have efficacy in treating Crohn’s disease. In addition, BB128 is being positioned for orphan disease indicaton and discovery trials are underway in 4 other novel disease indications.